Roland Kuiper
Senior Principal Investigator
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Background Rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation (ROHHAD) and neuroendocrine tumor (NET) is a very rare condition with an unknown etiology. While various potential causes have been hypothesized, including genetic and paraneoplastic autoimmune mechanisms, no definitive cause has been identified to date. This study aimed to explore whether patients with ROHHAD-NET share an underlying heritable genetic etiology. Results We identified five female patients clinically suspected of having ROHHAD(-NET); among them in two patients a NET was found: a ganglioneuroma and a low grade cerebellar ganglion cell tumor with BRAF mutation. To identify potential pathogenic germline genomic variants, whole genome sequencing (WGS) was performed on germline DNA from all five patients, including four patient-parent trios. Furthermore, optical genome mapping (OGM) was performed for two patients to detect germline structural variants (SVs). Rare single nucleotide variants (SNVs) and small insertions/deletions (InDels) were identified through WGS and rare SVs affecting (non)-coding or regulatory regions were analyzed using both WGS and OGM. We explored a de novo , inherited autosomal dominant and autosomal recessive inheritance scenario. However, no candidate variants in a recurrently affected gene locus or genomic region were identified in two or more patients. Conclusion Our comprehensive genome-wide data analysis did not reveal evidence of a monogenetic cause for ROHHAD-NET. Whereas these findings do not exclude a genetic etiology for ROHHAD-NET, they strengthen the hypothesis of an autoimmune origin for symptoms of ROHHAD.
Year:
2025
Despite compliance to surveillance colonoscopies, patients with Lynch Syndrome (LS) remain at a substantial lifetime risk of developing colorectal cancer, with rates as high as 30–52%. This highlights the need for better cancer prevention strategies. To assess the safety, feasibility, and immunogenicity of a preventive (neo)antigen-based dendritic cell (DC) vaccine, a phase I/II clinical trial was conducted involving 3 LS patients with a recent history of colorectal cancer (CRC) and 20 cancer free LS patients. All participants were HLA-A2 + and received autologous mature DC pulsed with HLA-A2-binding short peptide derived from carcinoembryonic antigen (CEA) and frameshift-derived neoantigens from caspase-5 and TGF-βRII. No grade 4 adverse events occurred in 22/23 patients and (neo)antigen-specific CD8 T cells were detected in nearly all patients. Post-vaccination, patients who developed T cells specific for the TGF-βRII neoantigen (39%) did not develop any LS-associated neoplasia with TGFBR2 mutation and have remained cancer-free for nearly 10 years. (ClinicalTrials.gov identifier- NCT01885702)
Year:
2025
Children harboring certain germline gene variants have an increased risk of developing myelodysplastic syndrome (MDS) and other hematopoietic malignancies (HM), such as leukemias and lymphomas. Recent studies have identified an expanding number of these predisposition genes, with variants most prevalent in children with MDS but also found in children with other HM. For some hematopoietic malignancy predispositions (HMP), specifically those with a high risk of MDS, early intervention through hematopoietic stem cell transplantation can favorably impact overall survival, providing a rationale for rigorous surveillance. A multidisciplinary panel of experts at the 2023 AACR Childhood Cancer Predisposition Workshop reviewed the latest advances in the field and updated prior 2017 surveillance recommendations for children with HMP. In addition to general guidance for all children with HMP, which includes annual physical examination, education about the signs and symptoms of HM, consultation with experienced providers, and early assessment by a hematopoietic stem cell transplantation specialist, the panel provided specific recommendations for individuals with a higher risk of MDS based on the affected gene. These recommendations include periodic and comprehensive surveillance for individuals with those syndromes associated with higher risk of MDS, including serial bone marrow examinations to monitor for morphologic changes and deep sequencing for somatic changes in genes associated with HM progression. This approach enables close monitoring of disease evolution based on the individual’s genetic profile. As more HMP-related genes are discovered and the disorders’ natural histories are better defined, these personalized recommendations will serve as a foundation for future guidelines in managing these conditions.
Year:
2024
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.
Year:
2024
Collaborators (18)
Sharon E. Plon
Professor and Assistant Dean
Baylor College of Medicine
Margreet A Veening
University of Amsterdam
Alison Bertuch
Professor
Baylor College of Medicine
Sharon Savage
Clinical Director
National Cancer Institute
Lisa J. McReynolds
National Institutes of Health
Carl Figdor
University of Twente
Marcin W Wlodarski
PI
St. Jude Children's Research Hospital
Luke D. Maese
Huntsman Cancer Institute
Vivian Y. Chang
University of California
Kim Erika Nichols
Full Member
St. Jude Children's Research Hospital
Gaëlle Bougeard
University of Rouen
Christopher C. Porter
Emory University School of Medicine
Lucy A. Godley
Northwestern Medicine
I. Jolanda M. de Vries
Department head
Radboudumc
Iris Nagtegaal
Professor of Gastrointestinal Pathology
Radboudumc
Sarah Scollon
Assistant Professsor/Genetic Counselor
Baylor College of Medicine
Julia Meade
Associate Professor of Pediatrics
West Virginia University
Hamish Scott
University of South Australia
Make your next move.
Prepare your application
Review drafts before you send them.